Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 3, 1999, Pages 275-282

  Sviri, Sigal ^b   Shpizen, Shoshi ^b   Leitersdorf, Eran ^b   Levy, Micha ^b   Caraco, Yoseph ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYMEPHENYTOIN; CYTOCHROME P450 2C19; CYTOCHROME P450 ISOENZYME; MEPHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; ENZYME ACTIVITY; ENZYME ISOLATION; FEMALE; GENE ACTIVITY; GENE DOSAGE; GENE FREQUENCY; GENE ISOLATION; GENE LOCATION; GENE MUTATION; GENETIC EPIDEMIOLOGY; HUMAN; HUMAN EXPERIMENT; ISRAEL; JEW; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POPULATION GENETICS; PRIORITY JOURNAL;

EID: 2042431033     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70106-2     Document Type: Article

References (42)

1. 1. Guengerich FP. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1996;24:521-33.
2. 2. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
3. 3. Adedoyin A, Parkash D, O'Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994;4:27-38.
4. 4. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
5. 5. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992;2:25-31.
6. 6. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997;62:619-28.
7. 7. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Then 1997;61:574-81.
8. 8. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994;37:237-42.
9. 9. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keundjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther 1992;51:507-12.
10. 10. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotypic differences in disposition and effect on gastrin levels of omeprazole: suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
11. 11. De Morias SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
12. 12. De Morias SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46: 594-8.
13. 13. Goldstein JA, Ishizaki T, Chiba K, De Morias SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64.
14. 14. Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R-and S-mephenytoin and comparison with intron4/exon5 G to A site mutation. Pharmacogenetics 1995;5:80-8.
15. 15. De Morias SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in Chinese population. Clin Pharmacol Ther 1995;58:404-11.
16. 16. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661-6.
17. 17. Edeki T, Goldstein JA, de Morias SMF, Hajiloo L, Butler M, Chapdelaine P, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996;6:357-60.
18. 18. Ferguson RL, de Morias SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356-61.
19. 19. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281:604-9.
20. 20. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquin and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-7.
21. 21. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
22. 22. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-Mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996;6:521-6.
23. 23. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, et al. Incidence of S-mephenytoin hydroxylation deficiency in Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-9.
24. 24. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
25. 25. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46:198-207.
26. 26. Nakamura K, Goto F, Ray WA, Mcallister CB, Jacqz E, Wilkinson GR, et al. Interethnic difference in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
27. 27. Kaneko A, Kaneko O, Taleo G, Bjorkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997;349:921-2.
28. 28. Zhang Y, Reviriego J, Lou YQ, Sjoqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990;48:496-502.
29. 29. Caraco Y, Wilkinson GR, Wood AJJ. Differences between Caucasians and Chinese in the in vivo inhibition of cytochrome P450s 2C19, 2D6 and 3A by omeprazole. Clin Pharmacol Ther 1996;60:396-404.
30. 30. Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995;58:62-74.
31. 31. Zhang Y, Blouin RA, Mcnamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S/R mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991;31:350-2.
32. 32. Masimirembwa C, Bertilsson L, Johansson I, Hasler J, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61.
33. 33. Price Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995;5:64-71.
34. 34. Hadidi HF, Irshaid Y, Woosley RL, Idle JR, Flockhart DA. S-Mephenytoin hydroxylation phenotypes in a Jordanian population. Clin Pharmacol Ther 1995;58:542-7.
35. 35. Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to MI mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998;45:27-9.
36. 36. Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH. Evidence for the effect of gender on activity of S-mephenytoin 4′-hydroxylation (CYP2C19) in a Chinese population. Pharmacogenetics 1997;7:115-9.
37. 37. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in white population. Clin Pharmacol Ther 1994;55:492-500.
38. 38. Brosen K, de Morias SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-7.
39. 39. Marandi T, Dahl ML, Rago L, Kiivet R, Sjoqvist F. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia. Eur J Clin Pharmacol 1997;53:257-60.
40. 40. Kupfer A, Desmond P, Patwardhan R, Schenker S, Branch RA. Mephenytoin hydroxylation deficiency: Kinetics after repeated doses. Clin Pharmacol Ther 1984;35:33-9.
41. 41. Setiabudy R, Chiba K, Kusaka M, Ishizaki T. Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping Southeastern Oriental subjects. Br J Clin Pharmacol 1992;33:665-6.
42. 42. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996;60:157-67.